Amgen (AMGN) Depreciation & Amortization (CF) (2009 - 2026)

Amgen's Depreciation & Amortization (CF) history runs 18 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 19.54% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $4.9 billion (down 12.26% YoY), while the FY2025 annual figure was $5.2 billion, down 7.6% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $1.1 billion, down from $1.1 billion in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $1.4 billion in Q2 2024, with the low at $828.0 million in Q2 2022.
• The 5-year median for Depreciation & Amortization (CF) is $1.1 billion (2025), against an average of $1.1 billion.
• The sharpest annual moves came in 2024 and 2026: Depreciation & Amortization (CF) soared 56.25% in 2024, then slipped 19.54% in 2026.
• Amgen's Depreciation & Amortization (CF) stood at $911.0 million in 2022, then soared by 51.48% to $1.4 billion in 2023, then increased by 1.23% to $1.4 billion in 2024, then dropped by 18.97% to $1.1 billion in 2025, then dropped by 1.41% to $1.1 billion in 2026.
• Business Quant data shows AMGN's Depreciation & Amortization (CF) at $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.3 billion in Q3 2025.